Evoke Pharma (NASDAQ:EVOK) and EVERSANA have announced that their abstract on the use of GIMOTI (nasal metoclopramide) in reducing healthcare visits for diabetic gastroparesis patients will be presented at the American Neurogastroenterology and Motility Society (ANMS) Annual Meeting. The study involved 294 patients and found that GIMOTI reduced the need for doctor's office, emergency department, inpatient, and outpatient visits. The announcement coincides with Gastroparesis Awareness Month.